MRNS — Marinus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $75.80m
- -$1.51m
- $30.99m
Annual income statement for Marinus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1.72 | 15.3 | 25.5 | 31 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 24 | 29.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 54.4 | 69.7 | 112 | 139 | 163 |
| Operating Profit | -54.4 | -67.9 | -97.1 | -114 | -132 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -54.1 | -67.5 | -98.8 | -16.4 | -143 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -54.1 | -67.5 | -98.8 | -19.8 | -141 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -54.1 | -67.5 | -98.8 | -19.8 | -141 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -54.1 | -76.4 | -98.8 | -19.8 | -141 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.97 | -2.8 | -2.65 | -2.28 | -2.58 |